SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia
暂无分享,去创建一个
F. Appelbaum | C. Willman | M. Othus | A. Advani | M. Sekeres | E. Copelan | A. List | Shannon L McDonough | D. Mulford | Shannon L. McDonough
[1] M. Levis,et al. Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. , 2012, Blood.
[2] J. Bourhis,et al. Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial. , 2012, Leukemia research.
[3] K. Hassan,et al. Clinical Manifestations of Acute Myeloid Leukemia , 2012 .
[4] R. Hills,et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[6] E. Estey,et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. , 2005, Blood.
[7] F. Appelbaum,et al. Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. , 2004, Blood.
[8] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] F. Appelbaum,et al. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. , 2003, Blood.
[10] F. Appelbaum,et al. Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. , 2003, Leukemia research.
[11] P. Thall,et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. , 2001, Blood.
[12] M. Slovak,et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. , 2000, Blood.
[13] G. Gahrton,et al. Lipoprotein receptors in acute myelogenous leukemia: failure to detect increased low-density lipoprotein (LDL) receptor numbers in cell membranes despite increased cellular LDL degradation. , 1998, The American journal of pathology.
[14] M. Vignetti,et al. Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] H. Kantarjian,et al. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. , 1996, Blood.
[16] D. Samid,et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] R. Clutterbuck,et al. Selective inhibition of primary acute myeloid leukaemia cell growth by lovastatin. , 1994, Leukemia.
[18] R. Clutterbuck,et al. Selective inhibition of primary acute myeloid leukaemia cell growth by simvastatin. , 1994, Leukemia.
[19] G. Gahrton,et al. Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[20] G. Gahrton,et al. Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation. , 1984, Blood.